About DxTerity
DxTerity is a Healthcare company based in Los Angeles (United States) founded in 2006. It operates as a provider of a direct-to-consumer, non-clinical genetic tests. DxTerity has raised $3.75 million across 7 funding rounds from investors including HHS. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its competitors include MedGenome, Foundation Medicine, ArcherDX, Personalis and Veritas Genetics and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
DxTerity was founded in 2006 and is headquartered in Los Angeles, United States. Operations focus on the genomics sector, where direct-to-consumer, non-clinical genetic tests are developed and offered. Proprietary DxDirect chemistry, combined with RT-PCR, enables assay creation and gene signature analysis through the NEAT ligation process. Fingerstick blood samples are collected, stabilized using the DxCollect system, and shipped via US mail for processing.
- Headquarters Los Angeles, United States
- SectorsHealthcare
- Website dxterity.com
- Social LinkedIn
- Total Equity Funding$3.75M (USD)
in 7 rounds
- Latest Funding Round$100K (USD), Series A
Jan 2015
- Investors
Funding Insights of DxTerity
DxTerity has successfully raised a total of $3.75M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $100 thousand completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.75M
- Total Rounds 7
- Last Round Series A — $100,000
- First Round $155,000
(Mar 2008)
- Investors Count 1
All 7 funding rounds of DxTerity with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in DxTerity
DxTerity has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for DxTerity
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DxTerity
14 people are tracked at DxTerity (4 in leadership, 10 in team).
| Name | Role | Group |
|---|---|---|
Robert Terbrueggen | CEO & Founder | Leadership |
James Healy | Co-Founder, CFO & SVP, Business Development | Leadership |
Aviva Jacobs | VP, Product Development | Leadership |
Aviva Jacobs PhD, PMP | Vice President of Product Development | Leadership |
Wijesuriya Hemani | Laboratory Operations Manager | Team |
Heather Ashby | Administrative Assistant | Team |
Brett Swansiger | CCO | Team |
Scott Beach | Product Development Engineer | Team |
Janet Salazar | Senior Research Associate | Team |
George Bui | Genomic Client Services | Team |
Yenbou Liu | Staff Scientist | Team |
Samuel Dixon | Sr. Scientist, Product Development | Team |
George Yeh, Ph.D. | Consultant - Bioinformatics and Data Science | Team |
Timothy Guyon | Principal Scientist | Team |
Complete people profiles for DxTerity
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DxTerity
3 dated milestones of DxTerity across 9 years, from founding to its latest funding, stage changes and deals.
- Founded DxTerity is founded.
- Funding First funding round of $155K.
- Funding Latest funding round, Series A, of $100K.
Competitors of DxTerity
DxTerity has 9 listed competitors in our database, 9 of them funded. They include MedGenome, Foundation Medicine, ArcherDX, Personalis and Veritas Genetics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medgenome.com | 2013 | Bengaluru, India | $264.5M | 922 | DNA sequencing, bioinformatics, and multiomics services are provided. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| veritasgenetics.com | 2014 | Danvers, United States | $53.38M | 14 | Genetic testing products for health risks and traits are offered. | |
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | – | RNA-sequencing transcriptome kits for health data analysis are developed. | |
| biofidelity.com | 2002 | Cambridge, United Kingdom | $59.91M | 28 | Molecular diagnostic assays are developed for target DNA sequence detection. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| brbiotech.com | 2014 | Guangzhou, China | $203.32M | – | Personalized cancer diagnostics are developed using genomic big data analysis. |
Detailed competitors of DxTerity
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DxTerity
The website of DxTerity (dxterity.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▼ 7.6% vs previous month
Websites whose visitors overlap most with DxTerity. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| eurolyser.com | 100% | 1K | #15,130,040 | View details |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as DxTerity (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dxterity
Complete news archive for DxTerity
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DxTerity
DxTerity was founded in 2006 and raised its 1st funding round 2 years after it was founded.
DxTerity is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
DxTerity is a funded company, having raised a total of $3.75M across 7 funding rounds to date. The company's 1st funding round was a Seed of $155K, raised on Mar 2008.
DxTerity was founded in 2006 and is headquartered in Los Angeles, United States. Operations focus on the genomics sector, where direct-to-consumer, non-clinical genetic tests are developed and offered. Proprietary DxDirect chemistry, combined with RT-PCR, enables assay creation and gene signature analysis through the NEAT ligation process. Fingerstick blood samples are collected, stabilized using the DxCollect system, and shipped via US mail for processing.
DxTerity's top competitors include Foundation Medicine, MedGenome and Personalis.
DxTerity has 1 investor. Key investors include HHS.